These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 14537120)

  • 21. ROC and localization ROC analyses of lesion detection in whole-body FDG PET: effects of acquisition mode, attenuation correction and reconstruction algorithm.
    Farquhar TH; Llacer J; Hoh CK; Czernin J; Gambhir SS; Seltzer MA; Silverman DH; Qi J; Hsu C; Hoffman EJ
    J Nucl Med; 1999 Dec; 40(12):2043-52. PubMed ID: 10616885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A; Ott K; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
    Delbeke D; Martin WH; Patton JA; Sandler MP
    Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional 2-[18F]fluoro-2-deoxy-D-glucose uptake varies in normal lung.
    Miyauchi T; Wahl RL
    Eur J Nucl Med; 1996 May; 23(5):517-23. PubMed ID: 8698055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
    Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
    Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
    Hong R; Halama J; Bova D; Sethi A; Emami B
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
    Conrad GR; Sinha P
    Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
    Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
    J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values.
    Jaskowiak CJ; Bianco JA; Perlman SB; Fine JP
    J Nucl Med; 2005 Mar; 46(3):424-8. PubMed ID: 15750154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultra-low peak voltage CT colonography: effect of iterative reconstruction algorithms on performance of radiologists who use anthropomorphic colonic phantoms.
    Shin CI; Kim SH; Lee ES; Lee DH; Hwang EJ; Chung SY; Lee JM; Han JK; Choi BI
    Radiology; 2014 Dec; 273(3):759-71. PubMed ID: 25010640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
    Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
    J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fuzzy clustering-based segmented attenuation correction in whole-body PET imaging.
    Zaidi H; Diaz-Gomez M; Boudraa A; Slosman DO
    Phys Med Biol; 2002 Apr; 47(7):1143-60. PubMed ID: 11996060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
    Christensen JD; Colby TV; Patz EF
    Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR.
    Ruhlmann V; Heusch P; Kühl H; Beiderwellen K; Antoch G; Forsting M; Bockisch A; Buchbender C; Quick HH
    MAGMA; 2016 Apr; 29(2):301-8. PubMed ID: 26667965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
    Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
    Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers.
    Nakasone Y; Inoue T; Oriuchi N; Takeuchi K; Negishi A; Endo K; Mogi K
    Ann Nucl Med; 2001 Dec; 15(6):505-12. PubMed ID: 11831398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.